News

Public · Published

Wells Fargo maintains Nurix Therapeutics at Overweight, lowers price target to $20 from $25

Wells Fargo kept its Overweight rating on Nurix Therapeutics but cut its price target to $20 from $25, a 20% reduction. The new target implies 22.5% downside from the November 3 closing price of $25.82.

Published:

Updated:

What happened

Wells Fargo kept its Overweight rating on Nurix Therapeutics but cut its price target to $20 from $25, a 20% reduction. The new target implies 22.5% downside from the November 3 closing price of $25.82.

Confirmed

Global impact / market context

The lower target signals Wells Fargo sees less potential value in Nurix shares than before, while retaining its positive rating. If investors give the revision weight, it could reduce demand for the stock and make it harder for Nurix to raise funds by selling shares.

Analyst inference

The five other recent analyst targets listed range from $32 to $36, above Wells Fargo’s new $20 target. This gap shows sharply different analyst expectations, but the article provides no explanation for the disagreement or evidence of a resulting market reaction.

Confirmed

What to watch

  1. Watch for any further changes to Wells Fargo’s rating or target; the article reports a lower target but says its Overweight rating remains unchanged. Analyst inference
  2. Compare future Nurix analyst targets with Wells Fargo’s $20 and the other recent targets of $32 to $36 to see whether views converge or remain divided. Analyst inference
  3. The article gives no company operating results or funding plans, so it does not establish whether analyst revisions will affect Nurix’s spending, revenue, or cash available. Confirmed

Evidence

  • Original source link unavailable